Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Wenjian Jin
Observed name:
Wen-Jian Jin
Institution:
Jiangxi Provincial Cancer Hospital
Observed institutions:
Nanchang University,
Soochow University,
Jiangxi Provincial Cancer Hospital,
The First People's Hospital of Changzhou
ORCID:
0000-0003-2714-0014
Observed ORCID:
0000-0003-2714-0014
OpenAlex ID:
A5016877010
Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki‐67/CD31
2021
·
Ning Zhong
, Wei Zhuang
, et al.
·
Journal of Cellular and Molecular Medicine
·
31
PDF
GPER-Induced ERK Signaling Decreases Cell Viability of Hepatocellular Carcinoma
2021
·
Yu-an Qiu
, Jianping Xiong
, et al.
·
Frontiers in Oncology
·
31
PDF
MiR-331-3p Inhibition of the Hepatocellular Carcinoma (HCC) Bel-7402 Cell Line by Down-Regulation of E2F1
2019
·
Wenjian Jin
, Ning Zhong
, et al.
·
Journal of Nanoscience and Nanotechnology
·
25
Antitumor Activity of Chloroquine in Combination with Cisplatin in Human Gastric Cancer Xenografts
2015
·
Hui-Qing Zhang
, Nian Fang
, et al.
·
Asian Pacific Journal of Cancer Prevention
·
24
PDF
E-cadherin and calretinin as immunocytochemical markers to differentiate malignant from benign serous effusions
2004
·
Dong-Nan He
, Hua-Sheng Zhu
, et al.
·
World Journal of Gastroenterology
·
14
PDF
Robotic-assisted pulmonary lobectomy with lung cancer in a patient with situs inversus totalis
2022
·
Chen Yang
, Wenjian Jin
, et al.
·
Journal of Cardiothoracic Surgery
·
10
PDF
Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial
2024
·
Shen Zhao
, Huaqiang Zhou
, et al.
·
Journal of Thoracic Oncology
·
9
PDF
Efficacy and safety of deulorlatinib (TGRX-326) in patients with locally advanced or metastatic ALK+ non–small cell lung cancer: A multicenter, open-label, pivotal phase 2 trial.
2026
·
Yunpeng Yang
, Zhehai Wang
, et al.
·
Journal of Clinical Oncology
Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial
2026
·
Jie Huang
, Gang Chen
, et al.
·
Journal of Thoracic Oncology
First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.
2023
·
Hongyun Zhao
, Yuxiang Ma
, et al.
·
Journal of Clinical Oncology
Pemetrexed as Second-line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer
2011
·
Wenjian Jin
·
The Practical Journal of Cancer
Show more works
View as search
Works count:
11
Citation count:
144
H-index:
7
I10-index:
6
Year
Topic
Type